Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Common Equity (2023 - 2025)

Historic Common Equity for Metagenomi (MGX) over the last 3 years, with Q3 2025 value amounting to $178.4 million.

  • Metagenomi's Common Equity fell 3023.23% to $178.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $178.4 million, marking a year-over-year decrease of 3023.23%. This contributed to the annual value of $234.9 million for FY2024, which is 27321.88% up from last year.
  • According to the latest figures from Q3 2025, Metagenomi's Common Equity is $178.4 million, which was down 3023.23% from $195.8 million recorded in Q2 2025.
  • Metagenomi's Common Equity's 5-year high stood at $275.6 million during Q1 2024, with a 5-year trough of -$135.6 million in Q4 2023.
  • Its 3-year average for Common Equity is $117.7 million, with a median of $195.8 million in 2025.
  • As far as peak fluctuations go, Metagenomi's Common Equity soared by 21499737.11% in 2024, and later plummeted by 3023.23% in 2025.
  • Over the past 3 years, Metagenomi's Common Equity (Quarter) stood at -$135.6 million in 2023, then surged by 273.22% to $234.9 million in 2024, then fell by 24.02% to $178.4 million in 2025.
  • Its last three reported values are $178.4 million in Q3 2025, $195.8 million for Q2 2025, and $212.7 million during Q1 2025.